In vitro susceptibility and multilocus sequence typing of Fusarium isolates causing keratitis

Rosa, Priscila Raupp da; Nunes, Andréia Castro de Paula; Borges, Rafael; Batista, Bruna Gerardon; Goldani, Luciano Zubaran

doi:10.1016/j.mycmed.2018.05.001

Cited by 14 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings agree with reports from different regions in the world where the most frequently identified species causing human infections belonged to the FSSC followed by the fujikuroi and oxysporum species complexes (Al-Hatmi et al, 2015, 2016b; Taj-Aldeen et al, 2016). In Brazil species of FSSC were the most commonly reported, followed by the fujikuroi species complex (Scheel et al, 2013) and oxysporum species complex (Dallé da Rosa et al, 2018). Future studies including larger numbers of isolates are warranted to establish the prevalence of rare Fusarium species in clinical settings.…”

Section: Discussionmentioning

confidence: 99%

Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil

et al. 2019

View full text Add to dashboard Cite

Fusarium is widely distributed in the environment and is involved with plant and animal diseases. In humans, several species and species complexes (SC) are related to fusariosis, i.e., F. solani SC, F. oxysporum SC, F. fujikuroi SC, F. dimerum, F. chlamydosporum, F. incarnatum-equiseti , and F. sporotrichoides . We aimed to investigate the susceptibility of Fusarium clinical isolates to antifungals and azole fungicides and identify the species. Forty-three clinical Fusarium isolates were identified by sequencing translation elongation factor 1-alpha ( TEF1 α) gene. Antifungal susceptibility testing was performed to the antifungals amphotericin B, itraconazole, voriconazole, posaconazole, and isavuconazole, and the azole fungicides difenoconazole, tebuconazole, and propiconazole. The isolates were recovered from patients with median age of 36 years (range 2–78 years) of which 21 were female. Disseminated fusariosis was the most frequent clinical form ( n = 16, 37.2%) and acute lymphoblastic leukemia ( n = 7; 16.3%) was the most commonly underlying condition. A few species described in Fusarium solani SC have recently been renamed in the genus Neocosmospora , but consistent naming is yet not possible. Fusarium keratoplasticum FSSC 2 ( n = 12) was the prevalent species, followed by F. petroliphilum FSSC 1 ( n = 10), N. gamsii FSSC 7 ( n = 5), N. suttoniana FSSC 20 ( n = 3), F. solani sensu stricto FSSC 5 ( n = 2), Fusarium sp. FSSC 25 ( n = 2), Fusarium sp. FSSC 35 ( n = 1), Fusarium sp. FSSC18 ( n = 1), F. falciforme FSSC 3+4 ( n = 1), F. pseudensiforme ( n = 1), and F. solani f. xanthoxyli ( n = 1). Amphotericin B had activity against most isolates although MICs ranged from 0.5 to 32 μg mL -1 . Fusarium keratoplasticum showed high MIC values (8–>32 μg mL -1 ) for itraconazole, voriconazole, posaconazole, and isavuconazole. Among agricultural fungicides, difenoconazole had the lowest activity against FSSC with MICs of >32 μg mL -1 for all isolates.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil

et al. 2019

View full text Add to dashboard Cite

show abstract

“…To date, due to the low efficacy of other polyene and azole drugs, natamycin (NAT), amphotericin B (AMB) and voriconazole (VCZ) are the most commonly used drugs in Fusarium keratitis [ 23 , 24 , 25 ]. Regarding allylamines, a retrospective study from China showed promising results of terbinafine used in smaller and shallower ulcers in a group of patients in which Fusarium was predominant isolate [ 26 ].…”

Section: Antifungalsmentioning

confidence: 99%

“…Despite the high molecular weight limiting penetration into the deeper ocular tissues and, hence, the need for frequent and prolonged administration, it remains a gold standard for fungal keratitis [ 32 , 33 , 34 ]. Its wide antifungal spectrum covers the majority of Fusarium species and it was shown in a number of in vitro and in vivo studies [ 23 , 34 ]. One meta-analysis suggested that, when compared to other antifungals, NAT was particularly effective in treating initial Fusarium keratitis [ 35 ].…”

Section: Antifungalsmentioning

confidence: 99%

Fusarium Keratitis—Review of Current Treatment Possibilities

Szaliński

Zgryźniak

Rubisz³

et al. 2021

JCM

View full text Add to dashboard Cite

In many parts of the world, fungi are the predominant cause of infectious keratitis; among which, Fusarium is the most commonly isolated pathogen. The clinical management of this ophthalmic emergency is challenging. Due to the retardation of the first symptoms from an injury and the inability to differentiate fungal from bacterial infections based on clinical symptoms and difficult microbial diagnostics, proper treatment, in many cases, is postponed. Moreover, therapeutical options of Fusarium keratitis remain limited. This paper summarizes the available treatment modalities of Fusarium keratitis, including antifungals and their routes of administration, antiseptics, and surgical interventions.

show abstract

“…The ATCC 36031 strain belonging to the American Type Culture Collection (ATCC) was used as quality control. All isolates are deposited in the library of the Applied Mycology Research Laboratory of the Federal University of Rio Grande do Sul and were identified by sequencing the ITS and EF + RPB2 regions 23,24 …”

Section: Methodsmentioning

confidence: 99%

Synergistic association of clioquinol with antifungal drugs against biofilm forms of clinical Fusarium isolates

Chaves

Amaral

Coutinho

et al. 2020

Mycoses

View full text Add to dashboard Cite

Summary Background The influence of biofilm on the complexity of fungal diseases has been reported in recent years, especially in non‐invasive mycoses such as keratitis and onychomycosis. The difficulty in treating cases of fusariosis in the human medical clinic exemplifies this situation, because when Fusarium spp. are present in the form of biofilm, the permeation of antifungal agents is compromised. Objectives This study proposes an association of clioquinol, an inhibitor of fungal cells with antifungal drugs prescribed to combat fusariosis in humans. Methods Susceptibility was assessed by microdilution in broth. Formation of biofilm by staining with violet crystal. Inhibition and removal of biofilm using the MTT colorimetric reagent. Time‐kill combination, hypoallergenicity test, cytotoxicity test and toxicity prediction by computer analysis were also performed. Results Clioquinol associated with voriconazole and ciclopirox inhibited biofilm formation. Possibly, clioquinol acts in the germination and elongation of hyphae, while voriconazole prevents cell adhesion and ciclopirox the formation of the extracellular polymeric matrix. The CLIO‐VRC association reduced the biofilm formation by more than 90%, while the CLIO‐CPX association prevented over 95%. None of the association was irritating, and over 90% of the leucocytes remained viable. Computational analysis does not reveal toxicity relevant to CLIO, whereas VRC and CPX showed some risks for systemic use, but suitable for topical formulations. Conclusions The combination of CLIO‐VRC or CLIO‐CPX proved to be a promising association strategy in the medical clinic, both in combating fungal keratitis and onychomycosis, since they prevent the initial process of establishing an infection, the formation of biofilm.

show abstract

In vitro susceptibility and multilocus sequence typing of Fusarium isolates causing keratitis

Cited by 14 publications

References 31 publications

Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil

Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil

Fusarium Keratitis—Review of Current Treatment Possibilities

Synergistic association of clioquinol with antifungal drugs against biofilm forms of clinical Fusarium isolates

Contact Info

Product

Resources

About